{"id":263096,"date":"2026-06-01T18:53:45","date_gmt":"2026-06-01T18:53:45","guid":{"rendered":"https:\/\/www.europesays.com\/se\/263096\/"},"modified":"2026-06-01T18:53:45","modified_gmt":"2026-06-01T18:53:45","slug":"dicot-pharma-far-japanskt-patent-for-lib-01","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/263096\/","title":{"rendered":"Dicot Pharma f\u00e5r japanskt patent f\u00f6r LIB-01"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Forskningsbolaget Dicot Pharma har beviljats ett nytt patent i Japan f\u00f6r den aktiva substansen i l\u00e4kemedelskandidaten LIB-01, med giltighet till 2043. Det framg\u00e5r av ett pressmeddelande.\n <\/p>\n<p>Patentet st\u00e4rker bolagets immateriella skydd p\u00e5 en viktig marknad. Motsvarande patent \u00e4r tidigare godk\u00e4nt i USA, medan ans\u00f6kningar p\u00e5g\u00e5r i flera andra l\u00e4nder.\n <\/p>\n<p>\u201dVi bedriver ett offensivt patentarbete med redan beviljade patent p\u00e5 flertalet nyckelmarknader. Det nya patentet i Japan ger ett brett och starkt skydd f\u00f6r LIB-01 p\u00e5 \u00e4nnu en stor och viktig marknad f\u00f6r nya behandlingar mot erektil dysfunktion. Ut\u00f6ver detta har flertalet nya patentans\u00f6kningar skickats in f\u00f6r att ytterlige st\u00e4rka det globala skyddet f\u00f6r LIB-01\u201d, s\u00e4ger Dicot Pharmas vd Elin Trampe.<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Stefan Linn\u00e9r<br \/>\n <br class=\"col-start-2\"\/><br \/>\n stefan.linner@finwire.se<br \/>\n <br class=\"col-start-2\"\/><br \/>\n Nyhetsbyr\u00e5n Finwire<\/p>\n","protected":false},"excerpt":{"rendered":"Forskningsbolaget Dicot Pharma har beviljats ett nytt patent i Japan f\u00f6r den aktiva substansen i l\u00e4kemedelskandidaten LIB-01, med&hellip;\n","protected":false},"author":2,"featured_media":263097,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,5842,70,71,34,31,33,32,30],"class_list":["post-263096","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-dicot-pharma","tag-economy","tag-ekonomi","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116676369288165260","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/263096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=263096"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/263096\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/263097"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=263096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=263096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=263096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}